mitapivat

News

Novo Nordisk preps filings for sickle cell drug etavopivat

Novo Nordisk has claimed a key win in its head-to-head race with Agios to bring an oral PKR activator to the market for sickle cell disease.

News

Agios' chief medical officer, Sarah Gheuens

Agios mulls early FDA filing for sickle cell therapy

Agios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months.

News

Agios shares slump on sickle cell disease data

Shares in Agios lost nearly half their value after it posted mixed clinical results from a phase 3 trial of its sickle cell disease therapy mitapivat.

Novo Nordisk preps filings for sickle cell drug etavopivat

Agios mulls early FDA filing for sickle cell therapy

Agios shares slump on sickle cell disease data

Hacking ring seeks to extort Novo Nordisk after cyberattack

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks